Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Insmed Inc (INSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,022,423
  • Shares Outstanding, K 77,666
  • Annual Sales, $ 9,840 K
  • Annual Income, $ -324,280 K
  • 60-Month Beta 3.04
  • Price/Sales 199.79
  • Price/Cash Flow N/A
  • Price/Book 12.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.87
  • Number of Estimates 5
  • High Estimate -0.56
  • Low Estimate -0.98
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +13.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.25 +17.03%
on 06/12/19
29.22 -10.88%
on 05/20/19
-3.10 (-10.64%)
since 05/17/19
3-Month
22.25 +17.03%
on 06/12/19
33.13 -21.39%
on 04/09/19
-3.71 (-12.47%)
since 03/18/19
52-Week
11.31 +130.24%
on 12/24/18
33.13 -21.39%
on 04/09/19
-0.58 (-2.18%)
since 06/18/18

Most Recent Stories

More News
Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief...

INSM : 26.04 (+2.92%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards...

INSM : 26.04 (+2.92%)
Insmed Announces Closing of Public Offering of Common Stock

Insmed Incorporated (Nasdaq: INSM) today announced the closing of the previously announced public offering of its common stock. Insmed issued and sold in the public offering 9,615,385 shares of common...

INSM : 26.04 (+2.92%)
Insmed Announces Proposed Public Offering of Common Stock

Insmed Incorporated (Nasdaq: INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the underwriters...

INSM : 26.04 (+2.92%)
New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3...

INSM : 26.04 (+2.92%)
Uptrend Call Working As Insmed Inc Stock Rises 44.1% (INSM)

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on January 7th, 2019 at $19.84. In approximately 4 months, Insmed Inc has returned 44.14% as of today's recent price of $28.59.

INSM : 26.04 (+2.92%)
Shares of INSM Up 40.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on January 7th, 2019 at $19.84. In approximately 4 months, Insmed Inc has returned 40.56% as of today's recent price of $27.88.

INSM : 26.04 (+2.92%)
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

INSM : 26.04 (+2.92%)
Insmed: 1Q Earnings Snapshot

BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Tuesday reported a loss of $74.2 million in its first quarter.

INSM : 26.04 (+2.92%)
Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter...

INSM : 26.04 (+2.92%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade INSM with:

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

2nd Resistance Point 26.91
1st Resistance Point 26.48
Last Price 26.04
1st Support Level 25.47
2nd Support Level 24.90

See More

52-Week High 33.13
Last Price 26.04
Fibonacci 61.8% 24.79
Fibonacci 50% 22.22
Fibonacci 38.2% 19.64
52-Week Low 11.31

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar